{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:46:04Z","timestamp":1793709964573,"version":"4.6.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81772672"],"award-info":[{"award-number":["81772672"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Program of Clinical Research Center of Neurological Disease","award":["ND2022B04"],"award-info":[{"award-number":["ND2022B04"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Leukocyte immunoglobulin-like receptor subfamily B2 (LILRB2) was reported to be an inhibitory molecule with suppressive functions. sEVs mediate communication between cancer cells and other cells. However, the existence of LILRB2 on sEVs in circulation and the function of sEVs-LILRB2 are still unknown. This study aims to investigate the role of LILRB2 in GBM and determine how LILRB2 in sEVs regulates tumor immunity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>LILRB2 expression in normal brain and GBM tissues was detected by immunohistochemistry, and the effect of LILRB2 on prognosis was evaluated in an orthotopic brain tumor model. Next, a subcutaneous tumor model was constructed to evaluate the function of pirb in vivo. The immune cells in the tumor sites and spleen were detected by immunofluorescence staining and flow cytometry. Then, the presence of pirb in sEVs was confirmed by WB. The percentage of immune cells after incubation with sEVs from GL261 (GL261-sEVs) or sEVs from GL261-pirb<jats:sup>+<\/jats:sup> (GL261-sEVs-pirb) was detected by flow cytometry. Then, the effect of pirb on sEVs was evaluated by a tumor-killing assay and proliferation assay. Finally, subcutaneous tumor models were constructed to evaluate the function of pirb on sEVs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>LILRB2 was overexpressed in human GBM tissue and was closely related to an immunosuppressive TME in GBM. Then, a protumor ability of LILRB2 was observed in subcutaneous tumor models, which was related to lower CD8\u2009+\u2009T cells and higher MDSCs (myeloid-derived suppressor cells) in the tumor and spleen compared to those of the control group. Next, we found that pirb on sEVs (sEVs-pirb) inhibits the function of CD8\u2009+\u2009T cells by promoting the formation and expansion of MDSCs. Furthermore, the protumor function of sEVs-pirb was demonstrated in subcutaneous tumor models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We discovered that LILRB2\/pirb can be transmitted between GBM cells via sEVs and that pirb on sEVs induces the formation and expansion of MDSCs. The induced MDSCs facilitate the formation of an immunosuppressive TME.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00262-023-03395-6","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T11:54:44Z","timestamp":1677758084000},"page":"2179-2193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["LILRB2-containing small extracellular vesicles from glioblastoma promote tumor progression by promoting the formation and expansion of myeloid-derived suppressor cells"],"prefix":"10.1007","volume":"72","author":[{"given":"Peitao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"issue":"4","key":"3395_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3322\/caac.21613","volume":"70","author":"ACAD Tan","year":"2020","unstructured":"Tan ACAD, L\u00f3pez GY, Malinzak M, Friedman HS, Khasraw M (2020) Management of glioblastoma: State of the art and future directions. CA Cancer J Clin 70(4):299\u2013312","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"3395_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"RMW Stupp","year":"2005","unstructured":"Stupp RMW, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987\u2013996","journal-title":"N Engl J Med"},{"issue":"1","key":"3395_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","volume":"20","author":"JHGM Sampson","year":"2020","unstructured":"Sampson JHGM, Fecci PE, Ashley DM (2020) Brain immunology and immunotherapy in brain tumours. Nat Rev Cancer 20(1):12\u201325","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"3395_CR4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","volume":"15","author":"MXY Lim","year":"2018","unstructured":"Lim MXY, Bettegowda C, Weller M (2018) Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol 15(7):422\u2013442","journal-title":"Nat Rev Clin Oncol"},{"issue":"13","key":"3395_CR5","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","volume":"33","author":"RJRB Motzer","year":"2015","unstructured":"Motzer RJRB, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, Margolin KA, Plimack ER, Lambert AM, Waxman IM, Hammers HJ (2015) Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II Trial. J Clin Oncol 33(13):1430\u20131437","journal-title":"J Clin Oncol"},{"issue":"8","key":"3395_CR6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","volume":"18","author":"BSP Sangro","year":"2021","unstructured":"Sangro BSP, Herv\u00e1s-Stubbs S, Melero I (2021) Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 18(8):525\u2013543","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3395_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/978-1-4614-3146-6_4","volume":"746","author":"P IF","year":"2012","unstructured":"IF P (2012) Basic concepts in glioma immunology. Adv Exp Med Biol 746:42\u201352","journal-title":"Adv Exp Med Biol"},{"issue":"8","key":"3395_CR8","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41582-018-0025-8","volume":"14","author":"MLMS Broekman","year":"2018","unstructured":"Broekman MLMS, Abels ER, Mempel TR, Krichevsky AM, Breakefield XO (2018) Multidimensional communication in the microenvirons of glioblastoma. Nat Rev Neurol 14(8):482\u2013495","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"3395_CR9","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/neuonc\/nop023","volume":"12","author":"JCGG Rodrigues","year":"2010","unstructured":"Rodrigues JCGG, Zhang L, Ibrahim G, Kelly JJ, Gustafson MP, Lin Y, Dietz AB, Forsyth PA, Yong VW, Parney IF (2010) Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol 12(4):351\u2013365","journal-title":"Neuro Oncol"},{"issue":"18","key":"3395_CR10","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1158\/1078-0432.CCR-15-0260","volume":"21","author":"MPLY Gustafson","year":"2015","unstructured":"Gustafson MPLY, Bleeker JS, Warad D, Tollefson MK, Crispen PL, Bulur PA, Harrington SM, Laborde RR, Gastineau DA, Leibovich BC, Cheville JC, Kwon ED, Dietz AB (2015) Intratumoral CD14+ Cells and Circulating CD14+HLA-DRlo\/neg monocytes correlate with decreased survival in patients with clear cell renal cell carcinoma. Clin Cancer Res 21(18):4224\u20134233","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3395_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.semcancer.2005.07.005","volume":"16","author":"PBI Serafini","year":"2006","unstructured":"Serafini PBI, Bronte V (2006) Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16(1):53\u201365","journal-title":"Semin Cancer Biol"},{"key":"3395_CR12","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150","volume":"7","author":"VBS Bronte","year":"2016","unstructured":"Bronte VBS, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI (2016) Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 7:12150","journal-title":"Nat Commun"},{"issue":"3","key":"3395_CR13","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"VPS Kumar","year":"2016","unstructured":"Kumar VPS, Tcyganov E, Gabrilovich DI (2016) The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol 37(3):208\u2013220","journal-title":"Trends Immunol"},{"issue":"4","key":"3395_CR14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ccr.2004.08.031","volume":"6","author":"LDL Yang","year":"2004","unstructured":"Yang LDL, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC (2004) Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6(4):409\u2013421","journal-title":"Cancer Cell"},{"issue":"2","key":"3395_CR15","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1158\/0008-5472.CAN-05-1299","volume":"66","author":"BPP Huang","year":"2006","unstructured":"Huang BPP, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM, Chen SH (2006) Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66(2):1123\u20131131","journal-title":"Cancer Res"},{"key":"3395_CR16","doi-asserted-by":"publisher","first-page":"5671","DOI":"10.1158\/0008-5472.CAN-16-0144","volume":"76","author":"ALMJ Chang","year":"2016","unstructured":"Chang ALMJ, Wainwright DA, Dey M, Rivetta CV, Yu D, Kanojia D, Pituch KC, Qiao J, Pytel P et al (2016) CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells. Cancer Res 76:5671\u20135682","journal-title":"Cancer Res"},{"issue":"5489","key":"3395_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.290.5489.84","volume":"290","author":"JVLL Ravetch","year":"2000","unstructured":"Ravetch JVLL (2000) Immune inhibitory receptors. Science 290(5489):84\u201389","journal-title":"Science"},{"key":"3395_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40364-020-00191-7","volume":"8","author":"QLJ Li","year":"2020","unstructured":"Li QLJ, Wang S, Wang J, Chen X, Zhou D, Fang Y, Gao A, Sun Y (2020) Overexpressed immunoglobulin-like transcript (ILT) 4 in lung adenocarcinoma is correlated with immunosuppressive T cell subset infiltration and poor patient outcomes. Biomark Res 8:11","journal-title":"Biomark Res"},{"issue":"7","key":"3395_CR19","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.7150\/thno.52435","volume":"11","author":"XGA Chen","year":"2021","unstructured":"Chen XGA, Zhang F, Yang Z, Wang S, Fang Y, Li J, Wang J, Shi W, Wang L, Zheng Y, Sun Y (2021) ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Theranostics 11(7):3392\u20133416","journal-title":"Theranostics"},{"issue":"6","key":"3395_CR20","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.ccell.2016.10.009","volume":"30","author":"ATB Becker","year":"2016","unstructured":"Becker ATB, Weiss JM, Kim HS, Peinado H, Lyden D (2016) Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell 30(6):836\u2013848","journal-title":"Cancer Cell"},{"issue":"23","key":"3395_CR21","doi-asserted-by":"publisher","first-page":"9621","DOI":"10.1158\/0008-5472.CAN-10-1722","volume":"70","author":"JSR Webber","year":"2010","unstructured":"Webber JSR, Mason MD, Tabi Z, Clayton A (2010) Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res 70(23):9621\u20139630","journal-title":"Cancer Res"},{"key":"3395_CR22","doi-asserted-by":"publisher","first-page":"14041","DOI":"10.1038\/ncomms14041","volume":"8","author":"YWD Wei","year":"2017","unstructured":"Wei YWD, Jin F, Bian Z, Li L, Liang H, Li M, Shi L, Pan C, Zhu D, Chen X, Hu G, Liu Y, Zhang CY, Zen K (2017) Pyruvate kinase type M2 promotes tumour cell exosome release via phosphorylating synaptosome-associated protein 23. Nat Commun 8:14041","journal-title":"Nat Commun"},{"issue":"12","key":"3395_CR23","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1038\/ncb1800","volume":"10","author":"JWT Skog","year":"2008","unstructured":"Skog JWT, van Rijn S et al (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 10(12):1470\u20131476","journal-title":"Nat Cell Biol"},{"issue":"1","key":"3395_CR24","doi-asserted-by":"publisher","first-page":"e1252013","DOI":"10.1080\/2162402X.2016.1252013","volume":"6","author":"NGM Javeed","year":"2017","unstructured":"Javeed NGM, Dutta SK et al (2017) Immunosuppressive CD14+HLA-DRlo\/neg monocytes are elevated in pancreatic cancer and \u201cprimed\u201d by tumor-derived exosomes. Oncoimmunology 6(1):e1252013","journal-title":"Oncoimmunology"},{"issue":"1","key":"3395_CR25","doi-asserted-by":"publisher","first-page":"1697028","DOI":"10.1080\/20013078.2019.1697028","volume":"9","author":"Y Tian","year":"2020","unstructured":"Tian Y et al (2020) Quality and efficiency assessment of six extracellular vesicle isolation methods by nano-flow cytometry. J Extracell Vesicles 9(1):1697028","journal-title":"J Extracell Vesicles"},{"issue":"1","key":"3395_CR26","doi-asserted-by":"publisher","first-page":"1535750","DOI":"10.1080\/20013078.2018.1535750","volume":"7","author":"C Thery","year":"2018","unstructured":"Thery C et al (2018) Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 7(1):1535750","journal-title":"J Extracell Vesicles"},{"issue":"1","key":"3395_CR27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13046-019-1085-3","volume":"38","author":"XGG Wang","year":"2019","unstructured":"Wang XGG, Guan H, Yu Y, Lu J, Yu J (2019) Challenges and potential of PD-1\/PD-L1 checkpoint blockade immunotherapy for glioblastoma. J Exp Clin Cancer Res 38(1):87","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"3395_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/neuonc\/nov172","volume":"18","author":"EKWJ Nduom","year":"2016","unstructured":"Nduom EKWJ, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, Burks JK, Fuller GN, Calin GA, Conrad CA, Creasy C, Ritthipichai K, Radvanyi L, Heimberger AB (2016) PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol 18(2):195\u2013205","journal-title":"Neuro Oncol"},{"issue":"12","key":"3395_CR29","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.1002\/ijc.31661","volume":"143","author":"SMD Harris-Bookman","year":"2018","unstructured":"Harris-Bookman SMD, Martin AM, Xia Y, Kim E, Xu H, Belcaid Z, Polanczyk M, Barberi T, Theodros D, Kim J, Taube JM, Burger PC, Selby M, Taitt C, Korman A, Ye X, Drake CG, Brem H, Pardoll DM, Lim M (2018) Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma. Int J Cancer 143(12):3201\u20133208","journal-title":"Int J Cancer"},{"key":"3395_CR30","doi-asserted-by":"crossref","unstructured":"Gao A et al. (2021) Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity. J Immunother Cancer. 9(3)","DOI":"10.1136\/jitc-2020-001536"},{"issue":"12","key":"3395_CR31","doi-asserted-by":"publisher","first-page":"5647","DOI":"10.1172\/JCI97570","volume":"128","author":"HM Chen","year":"2018","unstructured":"Chen HM et al (2018) Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. J Clin Invest 128(12):5647\u20135662","journal-title":"J Clin Invest"},{"issue":"8","key":"3395_CR32","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","volume":"27","author":"JM Pitt","year":"2016","unstructured":"Pitt JM et al (2016) Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol 27(8):1482\u20131492","journal-title":"Ann Oncol"},{"issue":"1","key":"3395_CR33","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-022-01335-y","volume":"15","author":"Y Wang","year":"2022","unstructured":"Wang Y et al (2022) Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy. J Hematol Oncol 15(1):118","journal-title":"J Hematol Oncol"},{"issue":"5","key":"3395_CR34","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.trecan.2021.01.004","volume":"7","author":"ED Carosella","year":"2021","unstructured":"Carosella ED, Gregori S, Tronik-Le Roux D (2021) HLA-G\/LILRBs: a cancer immunotherapy challenge. Trends Cancer 7(5):389\u2013392","journal-title":"Trends Cancer"},{"issue":"4","key":"3395_CR35","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acsnano.1c00672","volume":"15","author":"Y Xia","year":"2021","unstructured":"Xia Y et al (2021) Embryonic stem cell derived small extracellular vesicles modulate regulatory T cells to protect against ischemic stroke. ACS Nano 15(4):7370\u20137385","journal-title":"ACS Nano"},{"key":"3395_CR36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fnins.2016.00127","volume":"10","author":"MBV Basso","year":"2016","unstructured":"Basso MBV (2016) Extracellular vesicles and a novel form of communication in the brain. Front Neurosci 10:127","journal-title":"Front Neurosci"},{"issue":"6478","key":"3395_CR37","doi-asserted-by":"publisher","first-page":"eaau6977","DOI":"10.1126\/science.aau6977","volume":"367","author":"RLV Kalluri","year":"2020","unstructured":"Kalluri RLV (2020) The biology, function, and biomedical applications of exosomes. Science 367(6478):eaau6977","journal-title":"Science"},{"issue":"14","key":"3395_CR38","doi-asserted-by":"publisher","first-page":"e12182","DOI":"10.1002\/jev2.12182","volume":"10","author":"KW Witwer","year":"2021","unstructured":"Witwer KW et al (2021) Updating MISEV: evolving the minimal requirements for studies of extracellular vesicles. J Extracell Vesicles 10(14):e12182","journal-title":"J Extracell Vesicles"},{"issue":"1","key":"3395_CR39","doi-asserted-by":"publisher","first-page":"1703244","DOI":"10.1080\/20013078.2019.1703244","volume":"9","author":"MODL Catalano","year":"2019","unstructured":"Catalano MODL (2019) Inhibiting extracellular vesicles formation and release: a review of EV inhibitors. J Extracell Vesicles 9(1):1703244","journal-title":"J Extracell Vesicles"},{"issue":"4","key":"3395_CR40","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-019-0264-y","volume":"20","author":"D Daassi","year":"2020","unstructured":"Daassi D, Mahoney KM, Freeman GJ (2020) The importance of exosomal PDL1 in tumour immune evasion. Nat Rev Immunol 20(4):209\u2013215","journal-title":"Nat Rev Immunol"},{"issue":"24","key":"3395_CR41","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1038\/s41388-022-02298-7","volume":"41","author":"S Chen","year":"2022","unstructured":"Chen S et al (2022) Liver-specific overexpression of Gab2 accelerates hepatocellular carcinoma progression by activating immunosuppression of myeloid-derived suppressor cells. Oncogene 41(24):3316\u20133327","journal-title":"Oncogene"},{"key":"3395_CR42","doi-asserted-by":"publisher","first-page":"e2201734","DOI":"10.1002\/advs.202201734","volume":"2","author":"ZLX Li","year":"2022","unstructured":"Li ZLX, Fu S, Ren L, Cai H, Zhang H, Gu Z, Ma X, Luo K (2022) Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency. Adv Sci (Weinh) 2:e2201734","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"3395_CR43","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41467-022-28523-1","volume":"13","author":"VMNN Ravi","year":"2022","unstructured":"Ravi VMNN, Will P, Joseph K, Maier JP, K\u00fcckelhaus J, Vollmer L, Goeldner JM, Behringer SP, Scherer F, Boerries M, Follo M, Weiss T, Delev D, Kernbach J, Franco P, Schallner N, Dierks C, Carro MS, Hofmann UG, Fung C, Sankowski R, Prinz M, Beck J, Sali\u00e9 H, Bengsch B, Schnell O, Heiland DH (2022) T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10. Nat Commun 13(1):925","journal-title":"Nat Commun"},{"issue":"7","key":"3395_CR44","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.7150\/thno.52435","volume":"11","author":"X Chen","year":"2021","unstructured":"Chen X et al (2021) ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Theranostics 11(7):3392\u20133416","journal-title":"Theranostics"},{"issue":"2","key":"3395_CR45","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","volume":"177","author":"MHT Poggio","year":"2019","unstructured":"Poggio MHT, Pai CC, Chu B, Belair CD, Chang A, Montabana E, Lang UE, Fu Q, Fong L, Blelloch R (2019) Suppression of exosomal PD-l1 induces systemic anti-tumor immunity and memory. Cell 177(2):414\u2013427","journal-title":"Cell"},{"issue":"3","key":"3395_CR46","doi-asserted-by":"publisher","first-page":"eaar2766","DOI":"10.1126\/sciadv.aar2766","volume":"4","author":"FL Ricklefs","year":"2018","unstructured":"Ricklefs FL, Krenzlin H et al (2018) Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci Adv 4(3):eaar2766","journal-title":"Sci Adv"}],"updated-by":[{"DOI":"10.1007\/s00262-023-03426-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000}}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03395-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03395-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03395-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T13:02:51Z","timestamp":1686661371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03395-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["3395"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03395-6","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00262-023-03426-2","asserted-by":"object"}]},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]},"assertion":[{"value":"2 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00262-023-03426-2","URL":"https:\/\/doi.org\/10.1007\/s00262-023-03426-2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Second Affiliated Hospital of Soochow University and in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The patients provided their written informed consent to participate in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All the co-authors consent to publish the work in Journal of Nanobiotechonology.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}